MIRM - Mirum Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$142.55
DETAILS
HIGH:
$185.00
LOW:
$118.00
MEDIAN:
$140.00
CONSENSUS:
$142.55
UPSIDE:
44.54%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 521.3 | 336.9 | 186.4 | 77.1 | 19.1 | 0 | 0 | 0 |
| Cost of Revenue | 100.6 | 81.6 | 47.0 | 12.4 | 1.9 | 0.6 | 0.3 | 0 |
| Gross Profit | 420.7 | 255.2 | 139.3 | 64.7 | 17.2 | (0.6) | (0.3) | 0 |
| Operating Expenses | ||||||||
| R&D Expenses | 186.2 | 140.6 | 102.6 | 106.8 | 131.4 | 81.6 | 43.0 | 2.3 |
| SG&A Expenses | 257.0 | 202.2 | 145.9 | 89.1 | 59.2 | 22.7 | 11.8 | 0.6 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | (0.6) | (0.0) | 0 |
| Operating Expenses | 443.2 | 342.9 | 248.5 | 195.9 | 190.6 | 103.7 | 54.7 | 2.9 |
| Operating Income | ||||||||
| Operating Income | (22.1) | (87.6) | (109.2) | (131.2) | (173.4) | (104.3) | (54.7) | (2.9) |
| Interest Expense | 14.4 | 14.3 | 15.1 | 16.0 | 17.6 | 0.3 | 0 | 0 |
| Interest Income | 12.7 | 13.8 | 13.7 | 3.9 | 0.4 | 1.6 | 2.2 | 0.1 |
| Profitability | ||||||||
| EBITDA | 17.2 | (49.0) | (136.5) | (122.9) | (65.4) | (102.3) | (52.2) | (17.3) |
| EBIT | (7.0) | (72.6) | (147.3) | (126.1) | (66.4) | (102.9) | (52.5) | (17.3) |
| Income Before Tax | (21.4) | (86.9) | (162.4) | (142.1) | (84.0) | (103.3) | (52.5) | (17.3) |
| Income Tax Expense | 1.9 | 1.0 | 1.0 | (6.4) | 0.0 | 0.0 | 0.0 | 0 |
| Net Income | (23.4) | (87.9) | (163.4) | (135.7) | (84.0) | (103.3) | (52.6) | (17.3) |
| Per Share Data | ||||||||
| EPS (Basic) | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS (Diluted) | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -2.29 | -0.75 |
| Shares Outstanding | 50.2 | 47.5 | 40.9 | 33.8 | 30.3 | 25.3 | 23.0 | 23.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 296.7 | 222.5 | 286.3 | 28.0 | 31.3 | 142.1 | 12.0 | 52.0 |
| Short-Term Investments | 86.6 | 57.8 | 0 | 123.7 | 125.2 | 89.7 | 104.7 | 0 |
| Net Receivables | 123.3 | 78.3 | 68.0 | 24.0 | 3.3 | 0 | 0 | 0 |
| Inventory | 24.9 | 22.4 | 22.3 | 5.6 | 1.5 | 0 | 0 | 0 |
| Other Current Assets | 18.1 | 11.8 | 10.9 | 8.9 | 0 | 0 | 0 | 0.0 |
| Total Current Assets | 549.7 | 392.8 | 387.5 | 190.2 | 166.6 | 236.3 | 119.4 | 52.0 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 0 | 9.8 | 2.0 | 2.3 | 2.5 | 3.2 | 3.7 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 260.9 | 249.8 | 252.9 | 59.0 | 18.7 | 0 | 0 | 0 |
| Long-Term Investments | 8.1 | 12.5 | 0 | 0 | 5.0 | 0 | 23.3 | 0 |
| Other Non-Current Assets | 24.1 | 5.8 | 4.2 | 101.4 | 101.8 | 1.3 | 0.3 | 0 |
| Total Non-Current Assets | 293.1 | 278.0 | 259.1 | 162.7 | 128.1 | 4.5 | 27.3 | 0 |
| Total Assets | 842.8 | 670.8 | 646.6 | 352.9 | 294.7 | 240.9 | 146.7 | 52.0 |
| Current Liabilities | ||||||||
| Account Payables | 9.6 | 14.6 | 7.4 | 8.7 | 9.2 | 3.2 | 3.4 | 0.3 |
| Short-Term Debt | 2.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 146.8 | 32.2 | 20.9 | 15.8 | 12.0 | 6.1 | 2.2 | 0.0 |
| Total Current Liabilities | 205.8 | 126.6 | 87.1 | 64.7 | 42.6 | 18.5 | 13.1 | 2.4 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 309.8 | 308.1 | 306.4 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.0 | 2.5 | 3.8 | 4.5 | 0.0 | 0.0 | 0.0 | 59.8 |
| Total Non-Current Liabilities | 322.3 | 318.6 | 310.9 | 146.1 | 131.8 | 50.3 | 3.3 | 59.8 |
| Total Liabilities | 528.1 | 445.1 | 398.0 | 210.9 | 174.4 | 68.8 | 16.4 | 62.3 |
| Stockholders' Equity | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.0 |
| Retained Earnings | (667.5) | (644.2) | (556.2) | (392.8) | (257.2) | (173.2) | (69.9) | (17.3) |
| Accumulated Other Comprehensive Income | 0.4 | (0.4) | 1.6 | (0.2) | (0.0) | 0.1 | 0.1 | (66.8) |
| Total Stockholders' Equity | 314.7 | 225.6 | 248.7 | 142.0 | 120.2 | 172.1 | 130.3 | (10.3) |
| Total Liabilities & Equity | 842.8 | 670.8 | 646.6 | 352.9 | 294.7 | 240.9 | 146.7 | 52.0 |
| Debt Metrics | ||||||||
| Total Debt | 319.5 | 317.8 | 308.1 | 2.2 | 2.6 | 3.3 | 3.6 | 0 |
| Net Debt | 22.8 | 95.3 | 21.8 | (25.8) | (28.7) | (138.8) | (8.3) | (52.0) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | (23.4) | (87.9) | (163.4) | (135.7) | (84.0) | (103.3) | (52.6) | (17.3) |
| Depreciation & Amortization | 24.2 | 23.6 | 10.8 | 3.7 | 1.0 | 0.6 | 0.3 | 0 |
| Stock-Based Compensation | 71.4 | 48.4 | 35.0 | 27.0 | 23.1 | 12.6 | 6.1 | 0.1 |
| Change in Working Capital | (19.7) | 22.6 | (22.6) | (21.1) | 17.0 | 0.6 | 7.1 | 2.4 |
| Other Non-Cash Items | 3.2 | 3.6 | 69.3 | 12.5 | (90.4) | 0.3 | (0.3) | 12.1 |
| Operating Cash Flow | 55.8 | 10.3 | (70.9) | (120.1) | (132.8) | (89.1) | (39.4) | (0.4) |
| Investing Activities | ||||||||
| Capital Expenditure | (1.0) | (1.0) | (20.1) | (0.3) | (19.0) | (0.2) | (0.3) | (7.5) |
| Acquisitions | 0 | 0 | (212.8) | (8.0) | (19) | (38.1) | 127.5 | 0 |
| Purchases of Investments | (97.4) | (89.0) | (27.3) | (132.3) | (198.0) | (74.6) | (152) | 0 |
| Sales/Maturities of Investments | 74.4 | 19.9 | 153 | 140.3 | 157.6 | 112.7 | 24.5 | 0 |
| Other Investing Activities | 0 | (20) | (20) | 8.0 | 127 | 38.1 | (127.5) | (11.2) |
| Investing Cash Flow | (24.0) | (90.1) | (107.2) | 7.7 | 48.5 | 37.9 | (127.8) | (7.5) |
| Financing Activities | ||||||||
| Net Debt Issuance | 0 | 0 | 305.3 | 0 | 0 | 0 | 0 | 0.1 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (185.4) | 1.7 | 66.6 | 49.4 | 0 | 0 |
| Financing Cash Flow | 40.1 | 17.7 | 336.6 | 109.1 | 73.5 | 181.3 | 127.2 | 59.8 |
| Cash Position | ||||||||
| Net Change in Cash | 75.2 | (63.4) | 158.3 | (3.3) | (10.7) | 130.1 | (40.0) | 52.0 |
| Cash at Beginning | 222.9 | 286.3 | 128.0 | 131.3 | 142.1 | 12.0 | 52.0 | 0 |
| Cash at End | 298.2 | 222.9 | 286.3 | 128.0 | 131.3 | 142.1 | 12.0 | 52.0 |
| Free Cash Flow | 54.9 | 9.3 | (91.1) | (120.4) | (151.8) | (89.3) | (39.6) | (7.9) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 521.3 | 336.9 | 186.4 | 77.1 | 19.1 | 0 | 0 | 0 |
| Gross Profit | 420.7 | 255.2 | 139.3 | 64.7 | 17.2 | (0.6) | (0.3) | 0 |
| Operating Income | (22.1) | (87.6) | (109.2) | (131.2) | (173.4) | (104.3) | (54.7) | (2.9) |
| Net Income | (23.4) | (87.9) | (163.4) | (135.7) | (84.0) | (103.3) | (52.6) | (17.3) |
| EPS (Diluted) | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -2.29 | -0.75 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 296.7 | 222.5 | 286.3 | 28.0 | 31.3 | 142.1 | 12.0 | 52.0 |
| Total Assets | 842.8 | 670.8 | 646.6 | 352.9 | 294.7 | 240.9 | 146.7 | 52.0 |
| Total Debt | 319.5 | 317.8 | 308.1 | 2.2 | 2.6 | 3.3 | 3.6 | 0 |
| Stockholders' Equity | 314.7 | 225.6 | 248.7 | 142.0 | 120.2 | 172.1 | 130.3 | (10.3) |
| Cash Flow | ||||||||
| Operating Cash Flow | 55.8 | 10.3 | (70.9) | (120.1) | (132.8) | (89.1) | (39.4) | (0.4) |
| Capital Expenditure | (1.0) | (1.0) | (20.1) | (0.3) | (19.0) | (0.2) | (0.3) | (7.5) |
| Free Cash Flow | 54.9 | 9.3 | (91.1) | (120.4) | (151.8) | (89.3) | (39.6) | (7.9) |